SURUSS in perspective

Seminars in Perinatology

Volumn 29, Issue 4, 2005, Pages 225-235

  Wald, N J ^a   Rodeck, C ^b   Hackshaw, A K ^a   Rudnicka, A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN; ESTRIOL; INHIBIN A; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; AMNIOCENTESIS; BLOOD ANALYSIS; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DOWN SYNDROME; FEMALE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL SERUM; MATERNITY WARD; PREGNANCY; PRENATAL PERIOD; PRENATAL SCREENING; PRIORITY JOURNAL; SCREENING TEST; SECOND TRIMESTER PREGNANCY; STATISTICAL ANALYSIS; URINALYSIS;

ALPHA-FETOPROTEINS; CASE-CONTROL STUDIES; CHORIONIC GONADOTROPIN; COHORT STUDIES; DOWN SYNDROME; ESTRIOL; FALSE POSITIVE REACTIONS; FEMALE; FETAL DISEASES; HUMANS; INHIBINS; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; PROSPECTIVE STUDIES;

EID: 23644459097     PISSN: 01460005     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semperi.2005.05.006     Document Type: Conference Paper

References (27)

1. Wald NJ, Rodeck C, Hackshaw AK,, et al. First and second trimester antenatal screening for Down's syn-drome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10:56-104. Available at: http://www.ingentaselect.com/rsm/09691413/v10n2/contp1-1.htm.
2. N. Wald, C. Rodeck, A. Rudnicka Nuchal translucency and gestational age Prenat Diagn 24 2004 150 153
3. N. Wald, A. Hackshaw Tests using multiple markers N.J. Wald I. Leck Antenatal and Neonatal Screening (ed 2) 2000 Oxford University Press Oxford 23 57
4. J.K. Morris, D.E. Mutton, E. Alberman Revised estimates of maternal age specific live birth prevalence of Down's syndrome in the absence of antenatal screening and selective termination J Med Screen 9 2002 2 6
5. Office for National Statistics: Birth Statistics. Series FM1, Numbers 25-27. London: HMSO, 1996, 1997, 1998
6. R.E. Gilbert, C. Augood, R. Gupta Screening for Down's syn-drome effects, safety, and cost effectiveness of first and second tri-mester strategies BMJ 323 2001 423 425
7. N.J. Wald, A. Kennard, A. Hackshaw Antenatal screening for Down's syndrome J Med Screen 4 1997 181 247
8. C. Gosden, A. Tabor, I.L. Leck Amniocentesis and chorionic villus sampling N. Wald I. Leck Antenatal and Neonatal Screening (ed 2) 2000 Oxford University Press Oxford 470 516
9. K. Spencer, R. Bindra, A.B.J. Nix Delta-NT or NT MoM which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynaecol 22 2003 142 148
10. J.K. Morris, N.J. Wald, H.C. Watt Fetal loss in Down syndrome preg-nancies Prenat Diagn 19 1999 142 145
11. N.J. Wald, H.S. Cuckle, J.W. Densem Maternal serum screening for Down's syndrome in early pregnancy BMJ 297 1988 883 887
12. P. Royston, S.G. Thompson Model-based screening by risk with appli-cation to Down's syndrome Stat Med 11 1992 257 268
13. N.J. Wald, W.J. Huttly Validation of risk estimation using the quadruple test in prenatal screening for Down syndrome Prenat Diagn 19 1999 1083
14. N.J. Wald, A.K. Hackshaw, W. Huttly Empirical validation of risk screening for Down's syndrome J Med Screen 3 1996 185 187
15. R. Bindra, V. Heath, A. Liao One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks a pro-spective study of 15030 pregnancies Ultrasound Obstet Gynecol 20 2002 219 225
16. K. Spencer, V. Souter, N. Tul A screening programme for trisomy 21 at 10-14 weeks using fetal NT, maternal serum free β-hCG and PAPP-A Ultrasound Obstet Gynecol 13 1999 231 237
17. K. Spencer, C.E. Spencer, M. Power Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemical in a one-step clinic a review of three years prospective experience Br J Obstet Gynaecol 110 2003 281 286
18. N.J. Wald, J.W. Densem, L. George Pre-natal screening for Down's syndrome using inhibin-A as a serum marker Prenat Diagn 16 1996 143 153
19. N.J. Wald, J.W. Densem, L. George Inhibin-A in Down's syn-drome pregnancies revised estimate of standard deviation Prenat Diagn 17 1997 285 290
20. K.H. Nicolaides, R.J.M. Snijders, H.S. Cuckle Correct estimation of pa-rameters for ultrasound nuchal translucency screening Prenat Diagn 18 1998 519 521
21. I.M. de Graaf, E. Pajkrt, C.M. Bilardo Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency Prenat Diagn 19 1999 458 462
22. K. Spencer, R. Bindra, A.B. Nix Delta-NT or NT MoM which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynecol 22 2003 144 148
23. N.J. Wald, H.C. Watt, A.K. Hackshaw Integrated screening for Down's syndrome based on tests performed during the first and second trimes-ters N Engl J Med 341 1999 461 467
24. N.J. Wald, W.J. Huttly, A.K. Hackshaw Antenatal screening for Down's syndrome with the quadruple test Lancet 361 2003 835 836
25. J. Chen, D. Heffley, T. Beazoglu Utilization of amniocen-tesis by women screening positive for Down syndrome on the second-trimester Triple test Community Genet 3 2000 24 30
26. M. Whittle Down's syndrome screening where to now? Br J Obstet Gynaecol 108 2001 559 561
27. Y. Cooper In favour of motherhood Guardian 2001 (April 30)